Medical Advocates
HIV Infection/Disease
  Lipoatrophy  
General Reports
 Facial Lipoatrophy
Diagnostics/Monitoring
Clinical Management
Mitochondrial Disorders




 

 
HIV Metabolic Main Page   Main New/Newsworthy Home Page  
Last Update: February 03, 2012
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

General Reports
       
          Journal Papers, Abstracts, and Commentaries
 
 

FULL-TEXT PDF ARTICLE
 Economic Modeling of the Combined Effects of HIV-Disease, Cholesterol and Lipoatrophy
Based on ACTG 5142 Trial Data
Simpson KN, Dietz B, Baran R,
Cost Effectiveness and Resource Allocation 2011, 9:5
Paper

Human Immunodeficiency Virus Treatment-Induced Adipose Tissue Pathology and
Lipoatrophy: Prevalence and Metabolic Consequences.
Hammond E, McKinnon E, Nolan D.
 Clin Infect Dis. 2010 Jul 20.
Abstract

Lipoatrophy of the Footpad in HIV-Treated Patients Is Associated With Increased PAI-1.
Eriksson LE, Schonnesson LN, Bratt GA.
Biol Res Nurs. 2009 Nov 25.
Abstract

Statin therapy and changes in hip circumference among HIV-infected participants in the ALLRT Cohort.
Brown TT, Smurzynski M, Wu K, et al
 Antivir Ther. 2009;14(6):853-8
 Abstract

How Much Fat Loss Is Needed for Lipoatrophy to Become Clinically Evident?
Podzamczer D, Ferrer E, Martínez E, et al
AIDS Res Hum Retroviruses. 2009 Jun 5
 Abstract

Cost consequences of HIV-associated lipoatrophy.
Hornberger J, Rajagopalan R, Shewade A, Loutfy MR.
AIDS Care. 2009 May;21(5):664-71.
 Abstract

Mitochondrial RNA and DNA alterations in HIV lipoatrophy are linked to antiretroviral therapy
and not to HIV infection.
McComsey GA, Libutti DE, O'Riordan M, et al
Antivir Ther. 2008;13(5):715-22.
 Abstract

Impact of lipoatrophy on patient-reported outcomes in antiretroviral-experienced patients.
Doward LC, Dietz B, Wilburn J,  
AIDS Read. 2008 May;18(5):242-6, 252-6,
 Abstract
 
Androgen and gonadotropin patterns differ in HIV-1-infected men who develop lipoatrophy during
antiretroviral therapy: a case-control study.
Wunder DM, Fux CA, Bersinger NA, et al
HIV Med. 2008 May 3
 Abstract
 
Association of APOC3 Polymorphisms with Both Dyslipidemia and Lipoatrophy in
HAART-Receiving Patients.
 Bonnet E, Bernard J, Fauvel J, Massip P
 AIDS Res Hum Retroviruses. 2008 Feb 1
Abstract
 
Antiretroviral Therapies Associated with Lipoatrophy in HIV-Infected Women.
Tien PC, Barron Y, Justman JE, et al
AIDS Patient Care STDS. 2007 May;21(5):297-305
 Abstract
 
Pronounced lipoatrophy in HIV-infected men receiving HAART for more than 6 years
compared with the background population.
 Hansen A, Lindegaard B, Obel N, et al
HIV Med. 2006 Jan;7(1):38-45
 Abstract
 
FULL-TEXT ARTICLE
 Persistence of lipoatrophy after a four-year long interruption of antiretroviral therapy for
HIV1 infection: case report.
Parruti G, Marani Toro G.
BMC Infect Dis. 2005 Oct 3;5(1):80
 Paper
 
The role of diet, exercise and smoking in dyslipidaemia in HIV-infected patients with
lipodystrophy.
 Shah M, Tierney K, Adams-Huet B, et al
HIV Med. 2005 Jul;6(4):291-8.
 Abstract
 
Lipoatrophic men 44 months after the diagnosis of lipoatrophy are less
lipoatrophic but more hypertensive.
Bergersen B, Sandvik L, Ellingsen I, Bruun J.
HIV Med. 2005 Jul;6(4):260-7.
Abstract
 
Host factors may be more important than choice of antiretrovirals in the
development of lipoatrophy.
McComsey G, Maa JF.
AIDS Read. 2003 Nov;13(11):539-42, 559.
Abstract

Human immunodeficiency virus type 1-related lipoatrophy and lipohypertrophy are
associated with serum concentrations of leptin.
Nagy GS, Tsiodras S, Martin LD, et al.
Clin Infect Dis 2003 Mar 15;36(6):795-802
 Abstract

Incidence of and Risk Factors for Lipoatrophy (Abnormal Fat Loss) in Ambulatory
HIV-1-Infected Patients.
Lichtenstein KA, Delaney KM, Armon C, et al.
J Acquir Immune Defic Syndr 2003 Jan 1;32(1):48-56
 Abstract
 

  
              Conference Reports, Abstracts, and Posters
 
 
Assessment for sonographic grading scales of the body fat changes related to the lipoatrophic findings
of HIV patients in treatment with HAART
 R Gulizia, C Gervasoni, M Ortu, et al
(Ninth International Congress on Drug Therapy in HIV Infection)
 Abstract
 
POSTER
How Much Fat Loss Is Needed for Lipoatrophy to Become Clinically Evident?
D Podzamczer, E Ferrer, E Martinez, et al
(15 CROI)
PDF Poster   Abstract
 
POSTER
Lipoatrophy and Lipohypertrophy Are Independently Associated with Hypertension:
The Effect of Lipoatrophy but not Lipohypertrophy on Hypertension Is Independent
of Obesity
H Crane, C Grunfeld, R Harrington, M Kitahat
(15 CROI)
 PDF Poster   Abstract
 
Improvements in Hepatic and Adipocyte Insulin Sensitivity, Dyslipidemia, and Visceral Fat
during Leptin Treatment in HIV-infected Men with Lipoatrophy and Hypoleptinemia
 K Mulligan, H Khatami, J M Schwarz, et al
 (14 CROI)
 Abstract
 
FASl-670 and APOC3 Polymorphisms as Predictors of Lipoatrophy in Patients
Receiving ART
A Cossarizza, A Riva, B Zanone Poma, et al 
(13 CROI)
Abstract
 
Changes in Androgens and Gonadotropin during HAART and Their Association
with Development of Lipoatrophy in HIV-infected Men
 D Wunder, N Bersinger, R Weber, et al
(12 CROI)
 Abstract
 
Pronounced lipoatrophy without truncal fat accumulation in patients on long term
HAART compared with background population
AE Hansen, B Lindegaard, O Andersen, et al
 (15IAC)
 Abstract
 
Correlates of risk of concomitant presentation of lipoatrophy, lipohypertrophy and
hypertriglyceridemia in HIV-positive patients on first-line antiretroviral therapy
M Galli, A Cozzi-Lepri, A  Ridolfo, et al
 (15IAC)
 Abstract
 
Baseline Triglyceride Levels Predict Development of Lipoatrophy in Patients
Treated with Stavudine Extended-release/Prolonged-release Capsules or Stavudine
Immediate-release
 M Noor, C Dezii, C McLaren, et al.
 (11 CROI)
 Abstract
 
Incidence and Risk Factors for Lipoatrophy (Abnormal Fat Loss) in Ambulatory
HIV-1-Infected Patients
 K Lichtenstein, K Delaney, D Ward, et al
 (9 CROI)
 Abstract
 

Diagnostics/Monitoring
       
          Journal Papers, Abstracts, and Commentaries
 
 

Accuracy of Ultrasound Imaging Technique for Assessing Lipoatrophy in HIV-Infected Subjects.
Ferraioli G, Tinelli C, Scudeller L,  et al
Curr HIV Res. 2011 Aug 9.
Abstract


Assessment of Ultrasound for Use in Detecting Lipoatrophy in HIV-Infected Patients Taking
Combination Antiretroviral Therapy.
Viskovic K, Richman I, Klasnic K, et al 
AIDS Patient Care STDS. 2009 Jan 9.
 Abstract

Clinical Management
       
          Journal Papers, Abstracts, and Commentaries
 
 
Ritonavir-induced lipoatrophy and dyslipidaemia is reversed by the anti-inflammatory drug
leflunomide in a PPAR-γ-dependent manner.
 Mencarelli A, Francisci D, Renga B,  et al
Antivir Ther. 2012 Jan 25.
Abstract

Uridine supplementation in the treatment of HIV lipoatrophy: results of ACTG 5229.
McComsey GA, Walker UA, Budhathoki CB, et al
AIDS. 2010 Sep 7
 Abstract

Peripheral and visceral fat changes following a treatment switch to a non-thymidine analogue
or a nucleoside-sparing regimen in HIV-infected subjects with peripheral lipoatrophy:
results of ACTG A5110.
Tebas P, Zhang J, Hafner R, Tashima K, et al
 J Antimicrob Chemother. 2009 Mar 19.
Abstract
 
Current perspectives on the management and prevention of antiretroviral-associated lipoatrophy.
Phillips DR, Hay P.  
J Antimicrob Chemother. 2008 Aug 13.
Abstract
 
A Randomized, Placebo-Controlled Trial of Rosiglitazone for HIV-Related Lipoatrophy.
Cavalcanti RB, Raboud J, Shen S, et al
J Infect Dis. 2007 Jun 15;195(12):1754-61.
 Abstract

Plastic Surgical Approaches for HIV-associated Lipoatrophy.
 Moyle GJ. 
Curr HIV/AIDS Rep. 2005 Aug;2(3):127-31.
Abstract

Therapeutic approaches to combating lipoatrophy: do they work?
 Martin A, Mallon PW. 
J Antimicrob Chemother. 2005 Mar 10;
 Abstract
 
Interventions for managing antiretroviral therapy-associated lipoatrophy.
 Sutinen J. 
Curr Opin Infect Dis. 2005 Feb;18(1):25-33.
 Abstract
 
Improvement in lipoatrophy associated with highly active antiretroviral therapy
in human immunodeficiency virus-infected patients switched from stavudine
to abacavir or zidovudine: the results of the TARHEEL study.
 McComsey GA, Ward DJ, Hessenthaler SM, et al.  
 Clin Infect Dis. 2004 Jan 15;38(2):263-70
 Abstract
 
Prospective evaluation of the effects of antiretroviral therapy on body composition in
HIV-1-infected men starting therapy.
 Mallon PW, Miller J, Cooper DA, Carr A.
 AIDS 2003 May 2;17(7):971-9
 Abstract
 
Long-term metabolic consequences of switching from protease inhibitors to
efavirenz in therapy for human immunodeficiency virus -infected patients with lipoatrophy.
 Estrada V, De Villar NG, Larrad MT
Clin Infect Dis 2002 Jul 1;35(1):69-76
 Abstract
 
              Conference Reports, Abstracts, and Posters
 
 
POSTER
A 48-week Randomized Study of Uridine Supplementation vs Switch to TDF on Limb Fat,
Mitochondrial Function, Inflammation, and Bone Mineral Density in HIV Lipoatrophy
 G McComsey M A O’Riordan, J Choi, et al
 (17th CROI)
 PDF Poster     Abstract

Uridine Supplementation in the Management of HIV Lipoatrophy: Results of ACTG 5229
G McComsey, U Walker, C Budhathoki 
(17th CROI)
 Abstract

Effect of Pioglitazone on HIV-1 Related Lipoatrophy: a Randomized Double-Blind Placebo-
Controlled Trial (ANRS 113) with 130 patients
 L Slama, E Lanoy, M A Valentin,  et al
(13 CROI)
 Abstract
 

Toxicity and Efficacy of 3TC/EFV Associated with Stavudine or Abacavir in
Antiretroviral-naive ve Patients: 48-week Results of a Randomized Open and
Multicenter Trial (ABCDE Study)
 D Podzamczer, E Ferrer, P Sanchez, et  al
(11 CROI)
 Abstract

Mitochondrial Disorders
       
          Journal Papers, Abstracts, and Commentaries
 
 

Mitochondrial Abnormalities in HIV-Infected Lipoatrophic Patients Treated With
Antiretroviral Agents.
 Chapplain JM, Beillot J, Begue JM, et al 
J Acquir Immune Defic Syndr. 2004 Dec 1;37(4):1477-1488.
 Abstract
 

HIV Metabolic Main Page   Main New/Newsworthy Home Page  

Lipoatrophy